When used in combination therapy, STING agonists were found to help remodel the tumour vasculature, with the triple combination of ADU-S100 with vascular endothelial growth factor receptor 2 (VEGFR2) blockade and either anti-PD1 or anti-CTLA4 resulting in improved antitumour activity and overall survival [52]. The gene discussed is KDR; the disease is neoplasm.